We are live on ! Find out more
ABBV icon

AbbVie

1,501 hedge funds and large institutions have $72.7B invested in AbbVie in 2014 Q3 according to their latest regulatory filings, with 105 funds opening new positions, 581 increasing their positions, 589 reducing their positions, and 50 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more call options, than puts

Call options by funds: $1.05B | Put options by funds: $449M

110% more first-time investments, than exits

New positions opened: 105 | Existing positions closed: 50

16% more funds holding in top 10

Funds holding in top 10: 6980 (+11)

13% more capital invested

Capital invested by funds: $64.1B → $72.7B (+$8.59B)

7.96% more ownership

Funds ownership: 71.1%79.06% (+8%)

3% more funds holding

Funds holding: 1,4571,501 (+44)

1% less repeat investments, than reductions

Existing positions increased: 581 | Existing positions reduced: 589

Holders
1,501
Holders Change
+44
Holders Change %
+3.02%
% of All Funds
43.55%
Holding in Top 10
80
Holding in Top 10 Change
+11
Holding in Top 10 Change %
+15.94%
% of All Funds
2.32%
New
105
Increased
581
Reduced
589
Closed
50
Calls
$1.05B
Puts
$449M
Net Calls
+$597M
Net Calls Change
+$482M
Name Holding Trade Value Shares
Change
Change in
Stake
SB
151
Suntrust Banks
Georgia
$56.9M -$32.5M -586,021 -37%
STC
152
SEI Trust Company
Pennsylvania
$55.3M +$32.6M +586,636 +158%
MLICM
153
Metropolitan Life Insurance Company (MetLife)
New York
$54.9M -$803K -14,468 -1%
AAM
154
Aberdeen Asset Management
United Kingdom
$54.2M -$1.94M -34,894 -4%
M&T Bank
155
M&T Bank
New York
$52.9M +$42.1M +757,816 +479%
Neuberger Berman Group
156
Neuberger Berman Group
New York
$50.4M -$28.6M -515,941 -37%
D.E. Shaw & Co
157
D.E. Shaw & Co
New York
$49.6M -$312M -5,615,802 -87%
Aviva
158
Aviva
United Kingdom
$49.3M -$57.8K -1,041 -0.1%
Korea Investment Corp
159
Korea Investment Corp
South Korea
$49.3M -$2.92M -52,600 -6%
TG
160
TCW Group
California
$48.5M -$1.14M -20,594 -2%
NFA
161
Nationwide Fund Advisors
Ohio
$48M -$11.2M -202,316 -20%
Macquarie Group
162
Macquarie Group
Australia
$48M -$729K -13,128 -2%
Citadel Advisors
163
Citadel Advisors
Florida
$47.1M +$29.6M +533,331 +189%
EA
164
Euclid Advisors
Connecticut
$46.8M +$3.01M +54,200 +7%
BCIM
165
British Columbia Investment Management
British Columbia, Canada
$45.9M -$328K -5,901 -0.7%
AIG
166
American International Group
New York
$45.5M +$360K +6,490 +0.8%
YCMGA
167
York Capital Management Global Advisors
New York
$45.4M +$43.6M +785,554 New
FWCM
168
Ferguson Wellman Capital Management
Oregon
$45.2M +$16.5M +296,508 +61%
William Blair & Company
169
William Blair & Company
Illinois
$45M -$435K -7,828 -1%
Sanders Capital
170
Sanders Capital
Florida
$44.9M
DRZID
171
DePrince Race & Zollo Inc (DRZ)
Florida
$44.4M -$8.42M -151,715 -16%
DM
172
Deerfield Management
New York
$44.3M +$12.5M +225,000 +42%
HI
173
Honeywell International
North Carolina
$44.2M +$27.2M +490,000 +178%
BNP Paribas Financial Markets
174
BNP Paribas Financial Markets
France
$44M +$6.13M +110,469 +17%
SG
175
Swarthmore Group
Pennsylvania
$44M +$6.04M +108,725 +17%

ABBV Hedge Fund Activity: Q3 2014 in Review

1,501 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q3 2014, worth a combined $72.7B — up 13% from $64.1B a quarter earlier.

Buyers outnumbered sellers: 105 funds opened new ABBV positions and 50 closed out — a net gain of 55 holders — while 581 added to existing stakes and 589 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $1.35B. The largest seller was Norges Bank, cutting an estimated $634M.

  • 1,501 institutional investors held AbbVie (ABBV) as of Q3 2014, up from 1,457 in Q2 2014.
  • Funds reported $72.7B of AbbVie stock for Q3 2014, up 13% quarter-over-quarter.
  • 105 funds opened new AbbVie positions in Q3 2014 and 50 closed out, a net change of +55 holders.
  • The largest AbbVie buyer in Q3 2014 was Fidelity Investments, an estimated $1.35B added.
  • The largest AbbVie seller in Q3 2014 was Norges Bank, an estimated $634M sold.

Based on aggregated 13F filings for Q3 2014.